Orchid Pharma Board of Directors

Get the latest insights into the leadership at Orchid Pharma. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Mr. Ram Gopal Agarwal Chairman & Non-Exe.Director
Mr. Manish Dhanuka Managing Director
Mr. Mridul Dhanuka Whole Time Director
Mr. Arjun Dhanuka Non Executive Director
Mrs. Tanu Singla Independent Director
Dr. Dharam Vir Independent Director
Mr. Manoj Kumar Goyal Independent Director
Ms. Shubha Singh Independent Director

Orchid Pharma Share price

ORCHPHARMA

721.6

18.10 (-2.45%)
NSE
BSE
Last updated on 4 Sep, 2025 | 15:51 IST
BUYSELL
Today's High

749.00

Today's Low

720.00

52 Week Low

603.80

52 Week High

1997.40

The current prices are delayed, login to your account for live prices

Orchid Pharma FAQs

The board at Orchid Pharma consists of experienced professionals, including Mr. Ram Gopal Agarwal , Mr. Manish Dhanuka , and others, overseeing the company’s strategic and corporate governance.

Directors at Orchid Pharma are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Mr. Ram Gopal Agarwal is the current chairman at Orchid Pharma.

Executive directors at Orchid Pharma are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Orchid Pharma adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Orchid Pharma, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.